Michael Dougherty Joins bioAffinity Technologies as CFO

bioAffinity Technologies Inc. has hired Michael Dougherty as chief financial officer (CFO). Dougherty is an experienced C-level executive with more than 20 years in financial management and business strategy.
 
Dougherty reports directly to bioAffinity Technologies President and CEO Maria Zannes. Former CFO Michael Edwards is available as a consultant to ensure a smooth transition.
 
“We are delighted to welcome Mike to our executive leadership team. He brings a tremendous skill set developed in senior positions at Amazon and Russell Investments. His expertise in financial management will play an important role in the nationwide commercial rollout of CyPath Lung,” Zannes said. “His experience in strategy development and M&A will be crucial as we expand the CyPath brand into other indications and pursue therapeutics opportunities. I look forward to his input and leadership as we increase visibility for our Company among investors, analysts and the broader financial community.”
 
Most recently, Dougherty was CFO of Amazon’s Alexa commercial domains, where he was responsible for financial strategy over Alexa’s multi-billion-dollar investments in AI-generated customer experiences. Previously, Dougherty was CFO and operating officer of TINT, a user-generated content platform, and CFO at Filestack, a secure file handling service provider that was acquired by Idera Inc. Prior to that, Dougherty was CFO for Amazon Pay, where he supported Amazon’s digital payment wallet globally. Earlier in his career Dougherty held various finance positions at Russell Investments and Medisystems Corporation. He is a certified public accountant and a chartered global management accountant by the American Institute of Certified Public Accountants.
 
“As a finance executive at both large enterprise business units and private equity-backed growth firms, my focus has always been on operational excellence, legal and regulatory compliance, and stewardship of company resources. I am excited to join bioAffinity Technologies during this pivotal time in the evolution of its business,” Dougherty said. “CyPath Lung has significant potential to improve early-stage lung cancer diagnosis and extend lives. I look forward to leading the financial strategy to support its expansion and create value for our shareholders.”
 
bioAffinity Technologies Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. The company’s first product, CyPath Lung, is a noninvasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services. OncoSelect Therapeutics LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in-vitro to kill cancer cells without harm to normal cells. Research and optimization of the company’s platform technologies are conducted in its laboratories at The University of Texas at San Antonio.